A randomized, controlled UK trial published today in the Lancet shows that the antiviral drug molnupiravir doesn't prevent COVID-19 hospitalizations or deaths in high-risk, nonhospitalized, vaccinated ...

Among COVID-19 patients at risk for severe illness, the use of the antiviral molnupiravir (Lagevrio) within 5 days of infection was linked to reduced odds of persistent symptoms and related ...